Vijaya Diagnostic Centre Ltd (VIJAYA)
₹1,443.50
Mkt cap
₹15,081 Cr
P/E ratio
80.40
P/B
15.52
Div yield
0.14%
ROE
18.30%
ROCE
20.50%
EPS (TTM)
₹17.95
Book value
₹93
52W range
848–1,594
Sector
Healthcare
Price history
Previous close
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories. [1]
NSE VIJAYABSE 543350
Health check
Mixed
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−9.42% from high₹1,444
₹848+70.22% from low₹1,594
Current
₹1,443.50
Prev close
₹1,465.00
Day
−1.47%
Price performance
1D
−1.47%
1W
+3.89%
1M
−2.14%
3M
+6.12%
6M
+29.57%
1Y
+45.69%
YTD
+36.28%
Financials
Revenue, profit & margin
P/E ratio
80.4×
VIJAYA is 98% above the sector median of 40.7×
VIJAYA80.4×
Sector median40.7×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 139 | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 | 231 | |
| Expenses | 73 | 82 | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 | 132 | |
| Operating Profit | 48 | 57 | 52 | 63 | 61 | 76 | 67 | 69 | 74 | 82 | 86 | 96 | 99 | |
| OPM % | 40% | 41% | 39% | 41% | 39% | 42% | 40% | 40% | 39% | 41% | 42% | 44% | 43% | |
| Other Income | 6 | 7 | 3 | 3 | 4 | 5 | 5 | 5 | 7 | 6 | 5 | 2 | 9 | |
| Interest | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 | 11 | |
| Depreciation | 12 | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 | 25 | |
| Profit before tax | 35 | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 | 71 | |
| Tax % | 26% | 25% | 25% | 23% | 25% | 26% | 24% | 26% | 26% | 25% | 26% | 25% | 25% | |
| Net Profit | 26 | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 | 53 | |
| EPS in Rs | 2.57 | 3.26 | 2.53 | 3.27 | 3.06 | 4.10 | 3.43 | 3.40 | 3.76 | 4.21 | 4.20 | 4.66 | 5.16 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.25% · closed higher next day 10 of last 18
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 8 Nov '23 | 5 Feb '24◦ | 8 May '24◦ | 5 Aug '24 | 7 Nov '24◦ | 12 Feb '25◦ | 12 May '25◦ | 28 Jul '25 | 4 Nov '25 | 13 Feb '26 | 7 May '26◦ | 6 Aug '26◦ |
| Earnings day | +2.74% | +1.60% | +7.77% | +1.08% | +9.19% | −7.08% | −1.97% | +6.62% | +0.54% | −0.65% | +5.86% | −1.37% |
| +1 day | +4.05% | +7.89% | +18.49% | +2.93% | +4.52% | −10.20% | −5.91% | +4.60% | −0.16% | +1.44% | +11.13% | +1.66% |
| +5 days | +6.72% | +1.85% | +15.83% | +4.91% | −1.58% | −9.88% | −6.72% | +1.49% | +0.41% | +1.44% | +10.02% | +7.61% |
| +15 days | +10.61% | +7.25% | +19.59% | +15.49% | +12.86% | +2.66% | −2.70% | −1.49% | −1.28% | −4.81% | +2.72% | +6.04% |
| +30 days | +12.85% | +0.97% | +14.05% | +15.78% | +2.14% | −5.17% | −5.00% | −1.77% | −4.07% | −11.06% | +9.70% | +13.60% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202652.46%Promoter
Promoters52.46%0.05
FIIs10.67%0.98
DIIs32.49%0.88
Public4.38%0.16
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,911.70 | 57.07 | 32,088 | 0.73% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| Vijaya Diagnost. | ₹1,464.20 | 80.44 | 15,081 | 0.14% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| Metropolis Healt | ₹553.85 | 55.20 | 11,490 | 0.36% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| Thyrocare Tech. | ₹515.50 | 46.83 | 8,205 | 1.81% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹628.55 | 74.26 | 6,321 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| Suraksha Diagno. | ₹319.55 | 46.49 | 1,664 | 0.16% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Krsnaa Diagnost. | ₹497.95 | 16.33 | 1,615 | 0.40% | 16 | −19.12% | 211 | +19.95% | 12.71% |
| Median: 16 Co. | ₹377.02 | 40.70 | 1,027 | 0.07% | 13 | +25.77% | 103 | +19.10% | 21.90% |
Filings
Annual reports6
Concall transcripts47
PPTSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024PPTJun 2024TranscriptMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 OctBoard Meeting Intimation for Consider And Approve The Unaudited Financial Results 28 Oct - Board meeting on November 3, 2026 to approve Q2 and half-year FY2026 results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ending September 30, 2026.Closure of Trading Window 28 SepShareholder Meeting / Postal Ballot-Scrutinizer''s Report 26 Sep